| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
1 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey;
2 Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge;
3 Department of Medical Genetics, St Mary’s Hospital, Manchester;
4 Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton; and
5 Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambs, United Kingdom
Fanconi Anemia (FA) is an autosomal recessive syndrome characterized by congenital abnormalities, progressive bone marrow failure, and susceptibility to cancer. FA has eight known complementation groups and is caused by mutations in at least seven genes. Biallelic BRCA2 mutations were shown recently to cause FA-D1. Monoallelic (heterozygous) BRCA2 mutations confer a high risk of breast cancer and are a major cause of familial breast cancer. To investigate whether heterozygous variants in other FA genes are high penetrance breast cancer susceptibility alleles, we screened germ-line DNA from 88 BRCA1/2-negative families, each with at least three cases of breast cancer, for mutations in FANCA, FANCC, FANCD2, FANCE, FANCF, and FANCG. Sixty-nine sequence variants were identified of which 25 were exonic. None of the exonic variants resulted in translational frameshifts or nonsense codons and 14 were polymorphisms documented previously. Of the remaining 11 exonic variants, 2 resulted in synonymous changes, and 7 were present in controls. Only 2 conservative missense variants, 1 in FANCA and 1 in FANCE, were each found in a single family and were not present in 300 controls. The results indicate that FA gene mutations, other than in BRCA2, are unlikely to be a frequent cause of highly penetrant breast cancer predisposition.
This article has been cited by other articles:
|
|
 |
|
  D S P Tan, C Marchio, and J S Reis-Filho Hereditary breast cancer: from molecular pathology to tailored therapies J. Clin. Pathol., October 1, 2008; 61(10): 1073 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berwick, J. M. Satagopan, L. Ben-Porat, A. Carlson, K. Mah, R. Henry, R. Diotti, K. Milton, K. Pujara, T. Landers, et al. Genetic Heterogeneity among Fanconi Anemia Heterozygotes and Risk of Cancer Cancer Res., October 1, 2007; 67(19): 9591 - 9596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, D. P. Sejas, Y. Qiu, D. A. Williams, and Q. Pang Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence J. Cell Sci., May 1, 2007; 120(9): 1572 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rahman and R. H. Scott Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players Hum. Mol. Genet., April 15, 2007; 16(R1): R60 - R66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barroso, R.L. Milne, L.P. Fernandez, P. Zamora, J.I. Arias, J. Benitez, and G. Ribas FANCD2 associated with sporadic breast cancer risk Carcinogenesis, September 1, 2006; 27(9): 1930 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Taniguchi and A. D. D'Andrea Molecular pathogenesis of Fanconi anemia: recent progress Blood, June 1, 2006; 107(11): 4223 - 4233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Couch, M. R. Johnson, K. Rabe, L. Boardman, R. McWilliams, M. de Andrade, and G. Petersen Germ Line Fanconi Anemia Complementation Group C Mutations and Pancreatic Cancer Cancer Res., January 15, 2005; 65(2): 383 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C D Rogers, F J Couch, K Brune, S T Martin, J Philips, K M Murphy, G Petersen, C J Yeo, R H Hruban, and M Goggins Genetics of the FANCA gene in familial pancreatic cancer J. Med. Genet., December 1, 2004; 41(12): e126 - e126. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Surralles, S. P. Jackson, M. Jasin, M. B. Kastan, S. C. West, and H. Joenje Molecular cross-talk among chromosome fragility syndromes Genes & Dev., June 15, 2004; 18(12): 1359 - 1370. [Full Text] [PDF]
|
|
|
|
|
|
G. Narayan, H. Arias-Pulido, S. V. Nandula, K. Basso, D. D. Sugirtharaj, H. Vargas, M. Mansukhani, J. Villella, L. Meyer, A. Schneider, et al. Promoter Hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer Cancer Res., May 1, 2004; 64(9): 2994 - 2997. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
